A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Neoplasms, Colorectal · Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 47 (planned)
- Started
- Oct 20, 2025
- Main results expected
- Sep 28, 2028
- Fully finished
- Oct 27, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Number of participants with dose limiting toxicities (DLTs) per dose level
Measured over: Up to 28 days
Part 1: Number of participants with treatment emergent serious adverse events (TESAEs) and treatment emergent adverse events (TEAEs) by severity per dose level
Measured over: Up to approximately 33 months
Part 1: Number of participants with TESAEs and TEAEs by severity per dose level during DLT observation period
Measured over: Up to 28 days
Part 1: Number of participants with dosage modifications due to TEAEs per dose level
Measured over: Up to approximately 33 months
Part 2: Objective Response Rate (ORR)
Measured over: Up to approximately 33 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07213609 · record last updated 2026-09-16 · checked 2026-11-09 15:47 UTC